立即登录 | 免费注册
全部学科 | 内科学 | 心血管病学 | 内分泌学与糖尿病 | 神经病学 | 消化病学 | 呼吸病学 | 肿瘤学 | 妇产科学 | 骨科学
疾病中心： 高血压 | 冠心病 | 心力衰竭 | 心律失常 | 脂肪性肝病 | 糖尿病 | 卒中 | 慢性阻塞性肺病 | 子宫内膜异位症 | 乳腺癌 | 肺癌 | 结直肠癌 | 器官移植
Loading
当前位置：期刊中心 > 全球精选文摘 > 文摘导读

Arbaclofen Placarbil可减轻胃食管反流病患者的餐后反流症状

Arbaclofen Placarbil Decreases Postprandial Reflux in Patients With Gastroesophageal Reflux Disease
Gerson LB, Huff FJ, Hila A   |    2010/8/9 15:04:29   | 
Am J Gastroenterol  |   2010   |          View at Publisher
专家评级： ★★  |    循证评级： A   |  【全球专家评论】 |   打印| 推荐给好友
上一篇： 糜烂性食管炎和非糜烂性反流病患者反流发作与症状相关性的特点：使用联合阻抗-pH监测法的研究
下一篇： 异位妊娠与紧急避孕药：一项系统评价
Objectives:
Arbaclofen placarbil (AP), previously designated as XP19986, is an investigational prodrug of the active R-isomer of baclofen, a γ-aminobutyric acid agonist reflux inhibitor. The aim of this study was to assess the efficacy and safety of AP for decreasing meal-induced reflux episodes in patients with gastroesophageal reflux disease (GERD).

Methods:
We conducted a multicenter, randomized, double-blind, crossover study comparing single doses of AP with placebo. Different patients were enrolled at each of four escalating AP doses: 10, 20, 40, and 60mg. Enrolled patients had GERD symptoms at least three times a week and 20 reflux episodes on impedance/pH monitoring over a period of 2h. During study visits separated by periods of 3–7 days, patients received single doses of AP or placebo, followed by high-fat meals 2 and 6h after treatment. The primary end point was the number of reflux episodes over 12h after treatment.

Results:
A total of 50 patients were treated; efficacy analysis included 44 patients who received both AP and placebo and had technically satisfactory impedance/pH data. For the combined data from all dose cohorts, there was a statistically significant (P=0.01) decrease in reflux episodes over 12h after treatment with AP compared with placebo. The mean (s.d.) number of reflux episodes over 12h after AP treatment was 50.5 (27.2), with a mean reduction of 10.4 (23.9) episodes (17%) compared with placebo, for which a mean (s.d.) number of 60.9 (35.3) episodes was observed. Heartburn events associated with reflux were reduced during treatment with AP compared with placebo. AP seemed to be the most efficacious in the 60-mg dose group, and was well tolerated at all dose levels.

Conclusions:
AP decreased reflux and associated symptoms with good tolerability in patients with GERD.
关键词:

请登录后发表评论，点击此处登录。

慢性心衰诊治：规范中求突破
黄峻
2012-2-1
南京医科大学第一附属医院
房颤治疗：手段渐趋丰富 新型治疗药物不断涌现 非药物治疗备受关注
马长生
2012-2-1
首都医科大学附属北京安贞医院
注重老年人群特征 优化管理

刘梅林
2012-2-1
北京大学第一医院老年内科

 
相关文章